Latest Biotechnology News

Page 51 of 71
Paradigm Biopharmaceuticals has locked in a $27 million USD convertible note facility to fully fund its pivotal Phase 3 trial for knee osteoarthritis, ensuring operational momentum through key clinical milestones.
Ada Torres
Ada Torres
1 July 2025
Cambium Bio has secured ethics approvals in Australia and the US to initiate pivotal Phase 3 trials of Elate Ocular, targeting moderate to severe dry eye disease, with patient dosing expected in October 2025.
Ada Torres
Ada Torres
30 June 2025
Actinogen Medical has locked in up to $13.8 million in non-dilutive funding tied to its R&D tax incentives, bolstering its cash position as it advances a pivotal Alzheimer’s disease clinical trial.
Ada Torres
Ada Torres
30 June 2025
Actinogen Medical has enrolled its 100th participant in the XanaMIA phase 2b/3 Alzheimer’s trial, setting the stage for a critical interim analysis in January 2026 and final results by year-end.
Ada Torres
Ada Torres
30 June 2025
Memphasys Limited has submitted its CE Mark application for the Felix™ sperm separation device, targeting regulatory clearance within 6-12 months to unlock the lucrative European IVF market and accelerate approvals in other key regions.
Ada Torres
Ada Torres
30 June 2025
Microba Life Sciences has announced a $14.5 million capital raising, including a $2 million fully underwritten Securities Purchase Plan (SPP) and a $12.5 million Placement, aimed at fast-tracking commercialisation of its microbiome diagnostic tests in Australia and the UK.
Ada Torres
Ada Torres
27 June 2025
PYC Therapeutics has announced promising pre-clinical results for its RNA-based drug candidate PYC-002, targeting the genetic root of Phelan-McDermid Syndrome, with clinical trials expected to begin in 2026.
Ada Torres
Ada Torres
27 June 2025
Percheron Therapeutics has licensed HMBD-002, a promising immuno-oncology monoclonal antibody targeting VISTA, from Hummingbird Bioscience, marking a strategic pivot after recent setbacks. The company plans to initiate phase II trials in 2026, aiming to advance this novel cancer therapy toward commercialisation.
Ada Torres
Ada Torres
26 June 2025
Neuren Pharmaceuticals has been granted a US patent for NNZ-2591 to treat Pitt Hopkins syndrome, bolstered by promising Phase 2 clinical trial results and FDA orphan drug status.
Ada Torres
Ada Torres
26 June 2025
Biotron Limited has completed the initial safety phase of its lead Hepatitis B drug in animal studies, paving the way for efficacy testing in two distinct mouse models. This milestone marks a significant step forward in the company’s antiviral drug development program.
Ada Torres
Ada Torres
24 June 2025
Amplia Therapeutics has secured US ethics approval to launch a Phase 2 trial combining its drug narmafotinib with FOLFIRINOX chemotherapy for advanced pancreatic cancer, marking a key step in its clinical development.
Ada Torres
Ada Torres
24 June 2025
INOVIQ Limited has responded to ASX queries defending its announcement that its new CAR-NK-EV treatment killed 88% of breast and lung cancer cells in vitro, confirming compliance with disclosure rules and providing detailed study data.
Ada Torres
Ada Torres
23 June 2025